Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2016 call → NOWe need to determine if management describes a situation where counterparties (customers, partners) are currently losing something real and ongoing (a running meter) and are already behaving as if the meter is running. The question asks for both halves present as a present-tense reality, and that this dynamic is generating business meaningful relative to current size with contribution largely ahead. We need to analyze the transcript for such descriptions. Focus on commercial discussions, especially Opdivo, Yervoy, Eliquis, etc. Management talks about market dynamics, competition, reimbursement, etc. The key is whether management describes customers/parties facing accumulating losses if they don't have Bristol-Myers products. Typically, in pharma, the "counterparty" might be patients or payers, but often it's about unmet medical need. However, the question is about the company's product being essential such that delay costs the counterparty. This is a classic "running meter" if, for example, patients' conditions worsen without treatment, but that's generic. Or if payers lose money? Or if partners lose revenue? We need to look for specific statements where management describes that counterparties are already losing something because they don't have the product, and they are acting urgently. Possible mentions: In oncology, patients with cancer are losing time, but that's generic. More specifically, management talks about defending their position, competitive pressures, and launching new indications. They might mention that they are being "chased" by demand? Or that they have strong uptake. However, the question asks for "money, output, access, standing, time, or an opportunity" that counterparties are losing. In the transcript, management discusses commercial execution, but it's about their own performance, not about counterparties' costs. They talk about competition, but not about customers losing anything. There is no description of a "running meter" on the customer side. For example, they don't say "patients are losing lives each day without our drug" or "hospitals are incurring costs because they can't use our product." The discussion is more about their own sales and market share.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...